Compound diisopropylamine dichloroacetate tablets

This product activates the pyruvate dehydrogenase complex by inhibiting pyruvate dehydrogenase kinase, while increasing the oxygen uptake of liver cells, promoting lactic acid oxidation, reducing blood lactic acid levels, improving the body's acid-base metabolic balance, replenishing energy, and thus improving the energy metabolism of liver cells. The metabolite of this product, glycine, generates CO2, NH3, and N5N10-CH2-FH4 through the action of glycine lyase, providing energy for liver cell metabolism and providing methyl for choline synthesis; at the same time, diisopropylamine provides methyl under the action of ATP to promote choline synthesis. Choline reacts with liver fat to generate lecithin; lecithin, liver fat, cholesterol and lipoprotein combine to form lipoprotein; lipoprotein is easily soluble in plasma, thereby transporting fat from the liver to the outside of the liver and reducing fat accumulation in the liver. This product can reduce the concentration of glycerol and free fatty acids in the arteries, reduce the liver's absorption of glycerol, and stimulate triglycerides to be secreted into the blood in the form of VLDL, thereby effectively inhibiting the synthesis of triglycerides in the liver. This product can hinder the activity of the rate-limiting enzyme (HMGCoA reductase) for cholesterol synthesis. It affects the synthesis of cholesterol and fatty acids by inhibiting multiple steps of HMGCoA reductase. This product can improve liver function. It promotes the sequential methylation of membrane phospholipids, enhances the fluidity of liver cell membranes, and increases the activity of Na-K-ATPase, which is the main driving force for bile secretion and flow. It promotes the repair of damaged liver cells, improves the respiratory function and oxygen utilization of tissue cells. It increases the metabolic activity of fatty acids, accelerates the oxidation of fatty acids, and creates conditions for the recovery of liver function. This product is a typical targeted preparation, more than 90% of which participates in biochemical reactions in liver cells. This product can delay the release of dichloroacetic acid and reduce blood sugar and lactic acid levels. It inhibits the synthesis of triglycerides and cholesterol in the liver.

This product is a compound preparation, each tablet containing 20 mg of diisopropylamine dichloroacetate and 19.5 mg of calcium gluconate.

This product is white tablets.

Metabolic syndrome: Domestic: used for fatty liver, intrahepatic cholestasis, general liver dysfunction. Used for acute and chronic hepatitis, hepatomegaly, early liver cirrhosis. Foreign: In addition to the above indications, there are also sequelae of stroke, cerebral hemorrhage, cerebral softening, arteriosclerosis, hypertension, angina pectoris, myocardial infarction, myocarditis and various disorders caused by heart failure.

Oral administration: 1-2 tablets at a time, 1-3 times a day. For children, reduce the dosage by half or follow the doctor’s advice: for severe cases, double the dosage. Each course of treatment is 20 days.

Occasionally, drowsiness, headache, thirst, and rarely loss of appetite may occur, which may disappear on their own.

It is contraindicated for those who are allergic to this product.

Precautions for children: Not yet determined. Precautions for pregnancy and lactation: Not yet determined. Precautions for the elderly: Not yet determined.

Not yet clear

Keep away from light and store in a sealed container.

Each tablet contains 20 mg of diisopropylamine dichloroacetate and 19.48 mg of calcium gluconate

24 months

Hainan HEALTH CARE Laboratories Limited

• Founded in:

  1996-11-25

• Address:

  Guilinyang Industrial Zone, Meilan District, Haikou City, Hainan Province

• Tax NO.:

  91460100620025532X

• Registered Funds:

  $5.32 million

• Email:

  Log in to view